Kosuke Tanioka1, Mutsumi Okura2, Manami Inoue2, Koh-Ichiro Taniguchi1,3, Mitsutaka Taniguchi2, Toshiaki Hamano4, Naoko Tachibana5,6. 1. Center for Sleep-related Disorders, Department of Neurology, Kansai Electric Power Hospital, 2-1-7, Fukushima, Osaka, Fukushima, 553-0003, Japan. 2. Sleep Medical Center, Osaka Kaisei Hospital, Osaka, Japan. 3. Division of Sleep Medicine, Kansai Electric Power Medical Research Institute, Osaka, Japan. 4. Division of Neurology, Kansai Electric Power Medical Research Institute, Osaka, Japan. 5. Center for Sleep-related Disorders, Department of Neurology, Kansai Electric Power Hospital, 2-1-7, Fukushima, Osaka, Fukushima, 553-0003, Japan. nanaosaka@aol.com. 6. Division of Sleep Medicine, Kansai Electric Power Medical Research Institute, Osaka, Japan. nanaosaka@aol.com.
Abstract
OBJECTIVES: Preventing augmentation is the critical clinical issue for RLS treatment. As for augmentation in Asian RLS patients, there have been only four studies and the follow-up durations of these studies were not long. We investigated Japanese RLS patients with longer duration of treatment in a clinical setting. METHODS: This study is a retrospective assessment of 42 RLS patients with follow-up durations of longer than 18 months (78.4 ± 29.2, range 19-139) at two urban sleep centers in Osaka, Japan from May 2004 to April 2014. RESULTS: The mean age of first visit was 63.5 ± 14.1 years old and the estimated age of RLS onset was 47.9 ± 16.5 years old. Twenty-eight out of 42 patients were female. At initial evaluation, the mean International Restless Legs Scale score (IRLS score) was 22.0 ± 5.9. Thirty-one of 42 had already visited other clinics before coming to our sleep centers, and the number of clinics visited was 1.3 ± 0.6. Augmentation developed in two patients (4.8%), and the dosage of dopamine equivalent in patients with and without augmentation was 12.5 and 18.8 mg vs. 15.8 ± 17.7 mg. In the two RLS patients with augmentation, ferritin was 113.1 and 114.1 ng/mL, respectively, and the number of clinics before coming to our sleep centers was both three. CONCLUSIONS: The augmentation rate of Japanese RLS patients from our study is low compared with previous Western and Asian studies. It might be attributable to racial difference, lower dosage of dopaminergic treatment, and the level of ferritin.
OBJECTIVES: Preventing augmentation is the critical clinical issue for RLS treatment. As for augmentation in Asian RLS patients, there have been only four studies and the follow-up durations of these studies were not long. We investigated Japanese RLS patients with longer duration of treatment in a clinical setting. METHODS: This study is a retrospective assessment of 42 RLS patients with follow-up durations of longer than 18 months (78.4 ± 29.2, range 19-139) at two urban sleep centers in Osaka, Japan from May 2004 to April 2014. RESULTS: The mean age of first visit was 63.5 ± 14.1 years old and the estimated age of RLS onset was 47.9 ± 16.5 years old. Twenty-eight out of 42 patients were female. At initial evaluation, the mean International Restless Legs Scale score (IRLS score) was 22.0 ± 5.9. Thirty-one of 42 had already visited other clinics before coming to our sleep centers, and the number of clinics visited was 1.3 ± 0.6. Augmentation developed in two patients (4.8%), and the dosage of dopamine equivalent in patients with and without augmentation was 12.5 and 18.8 mg vs. 15.8 ± 17.7 mg. In the two RLS patients with augmentation, ferritin was 113.1 and 114.1 ng/mL, respectively, and the number of clinics before coming to our sleep centers was both three. CONCLUSIONS: The augmentation rate of Japanese RLS patients from our study is low compared with previous Western and Asian studies. It might be attributable to racial difference, lower dosage of dopaminergic treatment, and the level of ferritin.
Entities:
Keywords:
Augmentation; Dopaminergic treatment; Ferritin; Iron; Restless legs syndrome (RLS)
Authors: Richard P Allen; Daniel L Picchietti; Diego Garcia-Borreguero; William G Ondo; Arthur S Walters; John W Winkelman; Marco Zucconi; Raffaele Ferri; Claudia Trenkwalder; Hochang B Lee Journal: Sleep Med Date: 2014-05-17 Impact factor: 3.492
Authors: K Stiasny-Kolster; H Benes; I Peglau; M Hornyak; B Holinka; K Wessel; W Emser; M Leroux; R Kohnen; W H Oertel Journal: Neurology Date: 2004-12-28 Impact factor: 9.910
Authors: Richard P Allen; Crystal Chen; Diego Garcia-Borreguero; Olli Polo; Sarah DuBrava; Jeffrey Miceli; Lloyd Knapp; John W Winkelman Journal: N Engl J Med Date: 2014-02-13 Impact factor: 91.245
Authors: Diego Garcia-Borreguero; Michael H Silber; John W Winkelman; Birgit Högl; Jacquelyn Bainbridge; Mark Buchfuhrer; Georgios Hadjigeorgiou; Yuichi Inoue; Mauro Manconi; Wolfgang Oertel; William Ondo; Juliane Winkelmann; Richard P Allen Journal: Sleep Med Date: 2016-02-23 Impact factor: 3.492
Authors: Diego Garcia-Borreguero; Ronald Grunstein; Guruswamy Sridhar; Tilman Dreykluft; Pasquale Montagna; René Dom; Eric Lainey; Anne Moorat; James Roberts Journal: Sleep Med Date: 2007-05-18 Impact factor: 3.492
Authors: Diego García-Borreguero; Richard P Allen; Ralf Kohnen; Birgit Högl; Claudia Trenkwalder; Wolfgang Oertel; Wayne A Hening; Walter Paulus; David Rye; Arthur Walters; Juliane Winkelmann; Christopher J Earley Journal: Sleep Med Date: 2007-06-01 Impact factor: 3.492